Versigent Limited (VGNT)

We are reducing our rating on the shares of Versigent (VGNT; $45.78) from Outperform to Equal-Weight given the stock’s recent outperformance and since management is approaching its H2 outlook from a somewhat more conservative stance…

We still think the shares of Versigent (VGNT; $39.00; O/P) look undervalued, after it reported Q1 results, its first as a public company since being spun out from Aptiv (APTV; $57.11; O/P), which included a…

We initiate coverage of the shares of Versigent (VGNT; $28.34) with an Outperform and $35 target given our belief that the stock looks like a mispriced asset after being spun out by Aptiv (APTV; $60.63;…